Nosology and Classification of Genetic Skeletal Disorders: 2010 Revision

Matthew L. Warman,¹ Valerie Cormier-Daire,² Christine Hall,³ Deborah Krakow,^{4,5} Ralph Lachman,⁴ Martine LeMerrer,² Geert Mortier,⁶ Stefan Mundlos,⁷ Gen Nishimura,⁸ David L. Rimoin,⁴ Stephen Robertson,⁹ Ravi Savarirayan,¹⁰ David Sillence,¹¹ Juergen Spranger,¹² Sheila Unger,^{12,13} Bernhard Zabel,¹² and Andrea Superti-Furga^{12,14*}

¹Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, The Howard Hughes Medical Institute, Children's Hospital, Boston, Massachusetts

²Department of Genetics and INSERM U781, Paris Descartes University, Hôpital Necker Enfants Malades, Paris, France

³Institute of Child Health, University of London, London, UK

⁴Medical Genetics Institute, Steven Spielberg Building, Cedars-Sinai Medical Center, Los Angeles, California

⁵Departments of Orthopaedic Surgery and Human Genetics, UCLA, Los Angeles, California

⁶Department of Medical Genetics, University Hospital of Antwerp, University of Antwerp, Edegem, Belgium

⁷Institut für Medizinische Genetik, Charité Universitätsmedizin Berlin, Max-Planck-Institut für Molekulare Genetik, Berlin, Germany

⁸Department of Pediatric Imaging, Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan

⁹Department of Paediatrics and Child Health, Dunedin School of Medicine, Otago University, Dunedin, New Zealand

¹⁰Murdoch Children's Research Institute, Royal Children's Hospital, Department of Paediatrics, University of Melbourne, Victoria, Australia

¹¹Discipline of Genetic Medicine, The Children's Hospital at Westmead Clinical School, The University of Sydney, Westmead, Australia

¹²Centre for Pediatrics and Adolescent Medicine, Freiburg University Hospital, University of Freiburg, Freiburg, Germany

¹³Medical Genetics Service, University of Lausanne, CHUV—Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

¹⁴Department of Pediatrics, University of Lausanne, CHUV—Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Received 16 December 2010; Accepted 30 December 2010

Genetic disorders involving the skeletal system arise through disturbances in the complex processes of skeletal development, growth and homeostasis and remain a diagnostic challenge because of their variety. The Nosology and Classification of Genetic Skeletal Disorders provides an overview of recognized diagnostic entities and groups them by clinical and radiographic features and molecular pathogenesis. The aim is to provide the Genetics, Pediatrics and Radiology community with a list of recognized genetic skeletal disorders that can be of help in the

diagnosis of individual cases, in the delineation of novel disorders, and in building bridges between clinicians and scientists interested in skeletal biology. In the 2010 revision, 456 conditions were included and placed in 40 groups defined by molecular, biochemical, and/or radiographic criteria. Of these conditions, 316 were associated with mutations in one or more of 226 different genes, ranging from common, recurrent mutations to "private" found in single families or individuals. Thus, the Nosology is a hybrid between a list of clinically defined

How to Cite this Article:

Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A. 2011. Nosology and classification of genetic skeletal disorders: 2010 revision.

Am J Med Genet Part A 155:943–968.

The 9th ISDS meeting and the Nosology workshop were held in Boston in July 2009 and supported by The Manton Center for Orphan Disease Research, Children's Hospital, Boston, Massachusetts; Children's Orthopaedic Surgery Foundation, Inc., Boston, Massachusetts; The Osteogenesis Imperfecta Foundation, Gaithersburg, Maryland; Biomarin, Novato, California; and Enobia Pharma, Montreal, Quebec, Canada. The 2010 Nosology tables are available online at the International Skeletal Dysplasia Society web site (www.isds.ch).

*Correspondence to:

Andrea Superti-Furga, Centre Hospitalier Universitaire Vaudois (CHUV), Av. Decker, 2, 1011 Lausanne, Switzerland. E-mail: asuperti@unil.ch
Published online 15 March 2011 in Wiley Online Library (wileyonlinelibrary.com).
DOI 10.1002/ajmg.a.33909

disorders, waiting for molecular clarification, and an annotated database documenting the phenotypic spectrum produced by mutations in a given gene. The Nosology should be useful for the diagnosis of patients with genetic skeletal diseases, particularly in view of the information flood expected with the novel sequencing technologies; in the delineation of clinical entities and novel disorders, by providing an overview of established nosologic entities; and for scientists looking for the clinical correlates of genes, proteins and pathways involved in skeletal biology.

© 2011 Wiley-Liss, Inc.

Key words: skeletal genetics; osteochondrodysplasias; nosology; dysostoses; molecular basis of disease

INTRODUCTION

In the 1960s, accumulating evidence that genetic skeletal disorders were clinically and genetically heterogeneous prompted a group of international experts to prepare a document to reach an agreement on the nomenclature of what was then called “constitutional (or intrinsic) disorders of bone” [1970, 1971a,b,c,d; McKusick and Scott, 1971]. The “Nomenclature” was meant to bring together experts in radiology, clinical genetics, and pediatrics to agree on the denomination and classification of skeletal disorders, syndromes and metabolic diseases that were being newly described. Revisions have been prepared in 1977, 1983, 1992, and 1997 [1978, 1979, 1983, 1998, Rimoin, 1979; Spranger, 1992; Lachman, 1998]. Following the establishment of the International Skeletal Dysplasia Society (ISDS) in 1999, and to cope with the increasing complexity of information, revisions of the Nosology have been delegated to an expert group nominated ad hoc within the ISDS to ensure an adequate representation of clinical, radiological and molecular expertise (2001 and 2006 revisions) [Hall, 2002; Superti-Furga and Unger, 2007].

METHODS

The Nosology Group of the International Skeletal Dysplasia Society met in August 2009. A consensus was reached for changes to be made to the grouping of disorders and about the inclusion of individual disorders. The drafts were circulated after the meeting and an effort was made to monitor recent publications up to November 2010. The criteria used for inclusion of individual disorders were unchanged from the previous revision. They were:

- (1) Significant skeletal involvement, corresponding to the definition of skeletal dysplasias, metabolic bone disorders, dysostoses, and skeletal malformation and/or reduction syndromes.
- (2) Publication and/or listing in MIM (meaning that observations should not find their way into the Nosology before they achieve peer-reviewed publication status).
- (3) Genetic basis proven by pedigree or very likely based on homogeneity of phenotype in unrelated families.
- (4) Nosologic autonomy confirmed by molecular or linkage analysis and/or by the presence of distinctive diagnostic features and of observation in multiple individuals or families.

RESULTS

Four hundred fifty-six different conditions were included and placed in 40 groups defined by molecular, biochemical and/or radiographic criteria. Of these conditions, 316 (2006 revision: 215) were associated with one or more of 226 (2006 revision: 140) different genes. The results are presented in Table I. Within a group, disorders with known molecular basis have been listed preceding those with lesser degree of evidence; however, variants of the same disorder have been kept together.

The organization of groups has been further changed in comparison to the 2006 version. Two new groups based on a common affected molecule or biochemical pathway have been created (*TRPV4 group* and *Aggrecan group*). The TRPV4 group includes disorders that are relatively common and that constitute a new prototypic spectrum ranging from mild to lethal. Aggrecan is one of the important structural molecules in cartilage and it would not be surprising if more disorders would find their way into this group in the future. Thus, groups 1–8 are based on a common underlying gene or pathway.

Groups 9–17 are based on the localization of radiographic changes to specific bone structures (vertebrae, epiphyses, metaphyses, diaphysis, or combination thereof) or of the involved segment (rhizo, meso, or acro). Groups 18–20 are defined by macroscopic criteria in combination with clinical features (bent bones, slender bones, presence of multiple dislocations). Groups 21–25 and 28 take into account features of mineralization (increased or reduced bone density, impaired mineralization, stippling, osteolysis). Group 27 encompasses the large group of lysosomal disorders with skeletal involvement. Group 29 comprises disorders with so-called abnormal (previously “anarchic”) development of skeletal components such as exostoses, enchondromas, and ectopic calcification. It is particularly heterogeneous and may need to be revised in the future with the help of newer molecular data.

Group 23, comprising the osteopetrosis (OP) variants and related disorders, has been expanded following the identification of distinct genetic defects in various variants of osteopetrosis. The diversity of molecular mechanisms involved and the presence of clinical, biochemical and/or histologic features that distinguish between the various OP forms justify the subdivision of the “OP phenotype” in the many subtypes.

Group 25 (Osteogenesis Imperfecta and decreased bone density group) has had special attention. The Sillence classification, published 30 years ago, provided a first systematic clinical classification and made correlations to the inheritance pattern of individual clinical types [Sillence and Rimoin, 1978; Sillence et al., 1979a,b]. Today, a surprising genetic complexity of the molecular bases of OI has been revealed, and at the same time the extensive phenotypic variation arising from single loci has been documented clearly. It seemed therefore untenable to try and maintain tight correlations between “Sillence types” and their molecular basis. It was agreed upon to retain the Sillence classification as the prototypic and universally accepted way to classify the degree of severity in OI; and to free the Sillence classification from any direct molecular reference. Thus, the many genes that may cause osteogenesis imperfecta have been listed separately. The proliferation of “OI types” to reflect

TABLE I.

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
1. FGFR3 chondrodysplasia group						
Thanatophoric dysplasia type 1 (TD1)	AD	187600	4p16.3	FGFR3	FGFR3	Includes previous San Diego type
Thanatophoric dysplasia type 2 (TD2)	AD	187601	4p16.3	FGFR3	FGFR3	
Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN)	AD	See 187600	4p16.3	FGFR3	FGFR3	
Achondroplasia	AD	100800	4p16.3	FGFR3	FGFR3	
Hypochondroplasia	AD	146000	4p16.3	FGFR3	FGFR3	
Camptodactyly, tall stature, and hearing loss syndrome (CATSHL)	AD	187600	4p16.3	FGFR3	FGFR3	Inactivating mutation
Hypochondroplasia-like dysplasia(s)	AD, SP					Similar to hypochondroplasia but unlinked to FGFR3, probably heterogeneous; uncertain diagnostic criteria
See also group 33 for craniosynostoses syndromes linked to FGFR3 mutations, as well as LADD syndrome in group 39 for another FGFR3-related phenotype						
2. Type 2 collagen group and similar disorders						
Achondrogenesis type 2 (ACG2; Langer–Saldino)	AD	200610	12q13.1	COL2A1	Type 2 collagen	
Platyspondylic dysplasia, Torrance type	AD	151210	12q13.1	COL2A1	Type 2 collagen	See also severe spondyloskeletal dysplasias (group 13)
Hypochondrogenesis	AD	200610	12q13.1	COL2A1	Type 2 collagen	
Spondyloepiphyseal dysplasia congenita (SEDC)	AD	183900	12q13.1	COL2A1	Type 2 collagen	
Spondyloepimetaphyseal dysplasia (SEMD) Strudwick type	AD	184250	12q13.1	COL2A1	Type 2 collagen	
Kniest dysplasia	AD	156550	12q13.1	COL2A1	Type 2 collagen	
Spondyloperipheral dysplasia	AD	271700	12q13.1	COL2A1	Type 2 collagen	
Mild SED with premature onset arthrosis	AD		12q13.1	COL2A1	Type 2 collagen	Often associated with p.R719C and p.G474S mutations
SED with metatarsal shortening [formerly Czech dysplasia]	AD	609162	12q13.1	COL2A1	Type 2 collagen	Often associated with the p.R275C mutation
Stickler syndrome type 1	AD	108300	12q13.1	COL2A1	Type 2 collagen	Unlinked to either COL2A1, COL11A1, or COL11A2. See also COL9A1 for recessive form
Stickler-like syndrome(s)	AD					
3. Type 11 collagen group						
Stickler syndrome type 2	AD	604841	1p21	COL11A1	Type 11 collagen alpha-1 chain	
Marshall syndrome	AD	154780	1p21	COL11A1	Type 11 collagen alpha-1 chain	
Fibrochondrogenesis	AR	228520	1p21	COL11A1	Type 11 collagen alpha-1 chain	
Otospondylo-megaepiphyseal dysplasia [OSMED], recessive type	AR	215150	6p21.3	COL11A2	Type 11 collagen alpha-2 chain	

TABLE 1[(Continued)]

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Otospondylo-megaepiphyseal dysplasia (OSMED), dominant type [Weissenbacher–Zweymüller syndrome, Stickler syndrome type 3] <i>See also Stickler syndrome type 1 in group 2</i>	AD	215150	6p21.3	<i>COL11A2</i>	Type 11 collagen alpha-2 chain	
4. Sulfation disorders group						
Achondrogenesis type 1B (ACG1B)	AR	600972	5q32–33	<i>DTDST</i>	SLC26A2 sulfate transporter	Formerly known as Fraccaro type achondrogenesis
Atelosteogenesis type 2 (A02)	AR	256050	5q32–33	<i>DTDST</i>	SLC26A2 sulfate transporter	Includes de la Chapelle dysplasia, McAllister dysplasia, and “neonatal osseous dysplasia”
Diastrophic dysplasia (DTD)	AR	222600	5q32–33	<i>DTDST</i>	SLC26A2 sulfate transporter	See also multiple epiphyseal dysplasias and pseudoachondroplasia group (group 9)
MED, autosomal recessive type (rMED; EDM4)	AR	226900	5q32–33	<i>DTDST</i>	SLC26A2 sulfate transporter	Formerly “Pakistani type.” See also SEMD group (group 11)
SEMD, PAPSS2 type	AR	603005	10q23–q24	<i>PAPSS2</i>	PAPS-Synthetase 2	Includes recessive Larsen syndrome, humero-spinal dysostosis, and SED
Chondrodysplasia with congenital joint dislocations, CHST3 type (recessive Larsen syndrome)	AR	608637	10q22.1	<i>CHST3</i>	Carbohydrate sulfotransferase 3; chondroitin 6-sulfotransferase	Omani type
Ehlers–Danlos syndrome, CHST14 type (“musculo-skeletal variant”)	AR	601776	15q14	<i>CHST14</i>	Carbohydrate sulfotransferase 14; dermatan 4-sulfotransferase	Includes Adducted Thumb–Clubfoot syndrome
<i>See also group 7 and group 26 for other conditions with multiple dislocations</i>						
5. Perlecan group						
Dyssegmental dysplasia, Silverman-Handmaker type	AR	224410	1q36–34	<i>PLC</i> [<i>HSPG2</i>]	Perlecan	
Dyssegmental dysplasia, Rolland-Desbuquois type	AR	224400	1q36–34	<i>PLC</i> [<i>HSPG2</i>]	Perlecan	
Schwartz–Jampel syndrome [myotonic chondrodystrophy]	AR	255800	1q36–34	<i>PLC</i> [<i>HSPG2</i>]	Perlecan	Mild and severe forms; includes previous Burton dysplasia
6. Aggrecan group						
SED, Kimberley type	AD	608361	15q26	<i>AGC1</i>	Aggrecan	
SEMD, Aggrecan type	AR	612813	15q26	<i>AGC1</i>	Aggrecan	
Familial osteochondritis dissecans	AD	165800	15q26	<i>AGC1</i>	Aggrecan	
7. Filamin group and related disorders						
Frontometaphyseal dysplasia	XLD	305620	Xq28	<i>FLNA</i>	Filamin A	Some cases apparently lack FLNA mutations
Osteodysplasty Melnick–Needles	XLD	309350	Xq28	<i>FLNA</i>	Filamin A	

Otopalatodigital syndrome type 1 (OPD1)	XLD	311300	Xq28	FLNA	Filamin A	Includes Boomerang dysplasia, Piepkorn dysplasia, and spondylohumeroformal (giant cell) dysplasia
Otopalatodigital syndrome type 2 (OPD2)	XLD	304120	Xq28	FLNA	Filamin A	
Terminal osseous dysplasia with pigmentary defects (TODPD)	XLD	300244	Xq28	FLNA	Filamin A	
Atelosteogenesis type 1 (A01)	AD	108720	3p14.3	FLNB	Filamin B	
Atelosteogenesis type 3 (A03)	AD	108721	3p14.3	FLNB	Filamin B	Unlinked to FLNB
Larsen syndrome (dominant)	AD	150250	3p14.3	FLNB	Filamin B	
Spondylo-carpal-tarsal dysplasia	AR	272460	3p14.3	FLNB	Filamin B	
Spondylo-carpal-tarsal dysplasia	AR	272460				
Franck–ter Haar syndrome	AR	249420	5q35.1	SH3PXD2B	TKS4	Includes lethal and non-lethal forms
Serpentine fibula—polycystic kidney syndrome	AD?	600330				
See also group 4 for recessive Larsen syndrome and group 26 for conditions with multiple dislocations						
8. TRPV4 group						
Metatropic dysplasia	AD	156530	12q24.1	TRPV4	Transient receptor potential cation channel, subfamily V, member 4	Includes lethal and non-lethal forms
Spondyloepimetaphyseal dysplasia, Maroteaux type (Pseudo–Morquio syndrome type 2)	AD	184095	12q24.1	TRPV4	Transient receptor potential cation channel, subfamily V, member 4	
Spondylometaphyseal dysplasia, Kozlowski type	AD	184252	12q24.1	TRPV4	Transient receptor potential cation channel, subfamily V, member 4	
Brachyolmia, autosomal dominant type	AD	113500	12q24.1	TRPV4	Transient receptor potential cation channel, subfamily V, member 4	
Familial digital arthropathy with brachydactyly	AD	606835	12q24.1	TRPV4	Transient receptor potential cation channel, subfamily V, member 4	Unlinked to either DYNC2H1 or IFT80
9. Short-ribs dysplasias (with or without polydactyly) group						
Chondroectodermal dysplasia (Ellis–van Creveld)	AR	225500	4p16	EVC1	EvC gene 1	
Short rib—polydactyly syndrome (SRPS) type 1/3 (Saldino-Noonan/Verma-Naumoff)	AR	263510	4p16	EVC2	EvC gene 2	
SRPS type 1/3 (Saldino-Noonan/Verma-Naumoff)	AR	263510	11q22.3	DYNC2H1	Dynein, cytoplasmic 2, heavy chain 1	
SRPS type 1/3 (Saldino-Noonan/Verma-Naumoff)	AR	263510	3q25.33	IFT80	Intraflagellar transport 80 (homolog of)	Unlinked to either DYNC2H1 or IFT80
SRPS type 2 (Majewski)	AR	263520		NEK1	Nima related kinase 1	

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
SRPS type 4 [Beemer]	AR	269860				
Oral-facial-digital syndrome type 4 [Mohr—Majewski]	AR	258860				
Asphyxiating thoracic dysplasia [ATD; Jeune]	AR	208500	3q25.33	<i>IFT80</i>	Intraflagellar transport 80 (homolog of)	
Asphyxiating thoracic dysplasia [ATD; Jeune]	AR	208500	11q22.3	<i>DYNC2H1</i>	Dynein, cytoplasmic 2, heavy chain 1	
Asphyxiating thoracic dysplasia [ATD; Jeune]	AR	208500				Unlinked to either <i>DYNC2H1</i> or <i>IFT80</i>
Thoracolumbar/pelvic dysplasia [Barnes]	AD	187760				
See also <i>paternal UPD14 and cerebro-costo-mandibular syndrome</i>						
10. Multiple epiphyseal dysplasia and pseudoachondroplasia group						
Pseudoachondroplasia (PSACH)	AD	177170	19p12–13.1	<i>COMP</i>	COMP	
Multiple epiphyseal dysplasia [MED] type 1 (EDM1)	AD	132400	19p13.1	<i>COMP</i>	COMP	
Multiple epiphyseal dysplasia [MED] type 2 (EDM2)	AD	600204	1p32.2–33	<i>COL9A2</i>	Collagen 9 alpha-2 chain	
Multiple epiphyseal dysplasia [MED] type 3 (EDM3)	AD	600969	20q13.3	<i>COL9A3</i>	Collagen 9 alpha-3 chain	
Multiple epiphyseal dysplasia [MED] type 5 (EDM5)	AD	607078	2p23–24	<i>MATN3</i>	Matrilin 3	
Multiple epiphyseal dysplasia [MED] type 6 (EDM6)	AD	120210	6q13	<i>COL9A1</i>	Collagen 9 alpha-1 chain	
Multiple epiphyseal dysplasia [MED], other types						Some MED-like cases unlinked to known genes
Stickler syndrome, recessive type	AR	120210	6q13	<i>COL9A1</i>	Collagen 9 alpha-1 chain	
Familial hip dysplasia [Beukes]	AD	142669	4q35			
Multiple epiphyseal dysplasia with microcephaly and nystagmus [Lowry-Wood]	AR	226960				
See also <i>multiple epiphyseal dysplasia, recessive type (rMED; EDM4) in sulfation disorders (group 4), familial osteochondritis dissecans in the aggrecan group, as well as ASPED in the Acromelic group</i>						
11. Metaphyseal dysplasias						
Metaphyseal dysplasia, Schmid type [MCS]	AD	156500	6q21–22.3	<i>COL10A1</i>	Collagen 10 alpha-1 chain	
Cartilage-hair hypoplasia [CHH; metaphyseal dysplasia, McKusick type]	AR	250250	9p13	<i>RMRP</i>	RNA component of RNase H	Includes anauxetic dysplasia
Metaphyseal dysplasia, Jansen type	AD	156400	3p22–21.1	<i>PTHrP</i>	PTH/PTHrP receptor 1	Activating mutations—see also Blomstrand dysplasia [group 22, 23]
Eiken dysplasia	AR	600002	3p22–21.1	<i>PTHrP</i>	PTH/PTHrP receptor 1	Activating mutations—see also Blomstrand dysplasia [group 22, 23]

Metaphyseal dysplasia with pancreatic insufficiency and cyclic neutropenia [Shwachman–Bodian–Diamond syndrome, SBDS]	AR	260400	7q11	SBDS	SBDS protein	
Metaphyseal anadysplasia type 1	AD, AR	309645	11q22.2	<i>MMP13</i>	Matrix metalloproteinase 13	Includes SEMD Missouri type. Both dominant and recessive mutations described
Metaphyseal anadysplasia type 2	AR		20q13.12	<i>MMP9</i>	Matrix metalloproteinase 9	
Metaphyseal dysplasia, Spahr type	AR	250400				
Metaphyseal acroscaphodysplasia [various types]	AR	250215				
Genochondromatosis (type 1/type 2)	AD/SP	137360				
Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria	AR/SP	See 271550				
12. Spondylometaphyseal dysplasias (SMD)						
Spondyloenchondrodysplasia (SPENCD)	AR	271550	19p13.2	<i>ACPS</i>	Tartrate-resistant acid phosphatase (TRAP)	Includes combined immunodeficiency with autoimmunity and spondylometaphyseal dysplasia (MIM 607944)
Odontochondrodysplasia (OODCD)	AR	184260				
Spondylometaphyseal dysplasia, Sutcliffe type or corner fractures type	AD	184255				
SMD with severe genu valgum	AD	184253				Includes SMD Schmidt type and SMD Algerian type
SMD with cone-rod dystrophy	AR	608940				
SMD with retinal degeneration, axial type	AR	602271				
Dyspondyloenchondromatosis	SP					
Cheiro-spondyloenchondromatosis	SP					
See also <i>SMD Kozlowski (group TRPV4) disorders in group 11 as well as SMD Sedaghatian type in group 12; there are many individual reports of SMD variants</i>						
13. Spondylo-epi-(meta)-physeal dysplasias (SE(M)D)						
Dyggve–Melchior–Claussen dysplasia (DMC)	AR	223800	18q12–21.1	<i>DYM</i>	Dymeclin	Includes Smith–McCort dysplasia
Immuno-osseous dysplasia (Schimke)	AR	242900	2q34–36	<i>SMARCA1</i>	SWI/SNF-related regulator of chromatin subfamily A-like protein 1	
SED, Wolcott–Rallison type	AR	226980	2p12	<i>EIF2AK3</i>	Translation initiation factor 2-alpha kinase-3	
SEMD, Matrilin type	AR	608728	2p23–p24	<i>MATN3</i>	Matrilin 3	See also matrilin-related MED in group 8
SEMD, short limb—abnormal calcification type	AR	271665	1q23	<i>DDR2</i>	Discoidin domain receptor family, member 2	See also other dysplasias with stippling in group 20
SED tarda, X-linked (SED-XL)	XLR	313400	Xp22	<i>SEDL</i>	Sedlin	
Spondylo-megaepiphyseal-metaphyseal dysplasia (SMMD)	AR	613330	4p16.1	<i>NKX3-2</i>	NK3 Homeobox 2	

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Spondylodysplastic Ehlers–Danlos syndrome	AR	612350	11p11.2	<i>SLC39A13</i>	Zinc transporter ZIP13	
SPONASTRIME dysplasia	AR	271510				
SEMD with joint laxity (SEMD-JL)	AD	603546				
leptodactylic or Hall type						
SEMD with joint laxity (SEMD-JL)	AR	271640				
Beighton type						
Platyspondyly (brachyolmia) with amelogenesis imperfecta	AR	601216				
Late onset SED, autosomal recessive type	AR	609223				
Brachyolmia, Hobaek, and Toledo types	AR	271530, 271630				Nosologic relationship between the Toleado and Hobaek types of brachyolmia and recessive late-onset SED are unclear, distinctive criteria lacking so far
See also Brachyolmia (group 8), Opsismodysplasia (group 14), SEMDs (group 11), mucopolysaccharidosis type 4 (Morquio syndrome) and other conditions in group 26, as well as PPRD (SED with progressive arthropathy) in group 31						
14. Severe spondylodysplastic dysplasias						
Achondrogenesis type 1A (ACG1A)	AR	200600	14q32.12	<i>TRIP11</i>	Golgi-microtubule-associated protein, 210-kDa; GMAP210	
Schneckenbecken dysplasia	AR	269250	1p31.3	<i>SLC35D1</i>	Solute carrier family 35 member D1; UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter	
Spondylometaphyseal dysplasia, Sedaghatian type	AR	250220				
Severe spondylometaphyseal dysplasia (SMD Sedaghatian-like)	AR		7q11	<i>SBDS</i>	SBDS gene, function still unclear	
Opsismodysplasia	AR	258480				
See also Thanatophoric dysplasia, types 1 and 2 (group 1); ACG2 and Torrance dysplasia (group 2); Fibrochondrogenesis type 1B (ACG1B, group 4); and Metatropic dysplasia (TRPV4 group)						
15. Acromelic dysplasias						
Trichorhinophalangeal dysplasia types 1/3	AD	190350	8q24	<i>TRPS1</i>	Zinc finger transcription factor	
Trichorhinophalangeal dysplasia type 2 (Langer–Giedion)	AD	150230	8q24	<i>TRPS1 and EXT1</i>	Zinc finger transcription factor and Exostosin 1	Microdeletion syndrome; see also Multiple Cartilaginous Exostoses in group 28
Acrocapitofemoral dysplasia	AR	607778	2q33–q35	<i>IHH</i>	Indian hedgehog	
Cranioectodermal dysplasia (Levin–Sensenbrenner) type 1	AR	218330	3q21	<i>IFT122</i>	Intraflagellar transport 122 (Chlamydomonas, homolog of)	
Cranioectodermal dysplasia (Levin–Sensenbrenner) type 2	AR	613610	2p24.1	<i>WDR35</i>	WD repeat-containing protein 35	

Geleophytic dysplasia	AR	231050	9q34.2	<i>ADAMTSL2</i>	ADAMTS-like protein 2	Unlinked to ADAMTSL2 Includes acrolaryngeal dysplasia, previously known as Fantasy Island dysplasia or Tattoo dysplasia
Geleophytic dysplasia, other types	AR					
Acromicric dysplasia	AD	102370				Possibly related or allelic to Brachydactyly type C
Acrodysostosis	AD	101800				
Angel-shaped phalango-epiphyseal dysplasia (ASPED)	AD	105835				
Saldino–Mainzer dysplasia	AR	266920				
<i>See also short rib dysplasias group</i>						
16. Acromesomelic dysplasias						
Acromesomelic dysplasia type	AR	602875	9p13–12	<i>NPR2</i>	Natriuretic peptide receptor 2	
Maroteaux (AMDM)	AR	200700	20q11.2	<i>GDF5</i>	Growth and differentiation factor 5	Includes acromesomelic dysplasia Hunter-Thompson type; see also Brachydactyly (group 34)
Grebe dysplasia	AR					See also Brachydactyly (group 34)
Fibular hypoplasia and complex brachydactyly (Du Pan)	AR	228900	20q11.2	<i>GDF5</i>	Growth and differentiation factor 5	
Acromesomelic dysplasia with genital anomalies	AR	609441	4q23–24	<i>BMPR1B</i>	Bone morphogenetic protein receptor 1B	
Acromesomelic dysplasia, Osebold-Remondini type	AD	112910				
17. Mesomelic and rhizo-mesomelic dysplasias						
Dyschondrosteosis (Leri–Weill)	Pseudo-AD	127300	Xpter-p22.32	<i>SHOX</i>	Short stature—homeobox gene	Includes Reinhardt–Pfeiffer dysplasia, MIM 191400
Langer type (homozygous dyschondrosteosis)	Pseudo-AR	249700	Xpter-p22.32	<i>SHOX</i>	Short stature—homeobox gene	
Omodysplasia	AR	258315	13q31–q32	<i>GPC6</i>	Glypican 6	Existence of “dominant omodysplasia” (MIM 164745) remains to be confirmed
Robinow syndrome, recessive type	AR	268310	9q22	<i>ROR2</i>	Receptor tyrosine kinase-like orphan receptor 2	Includes previous costo-vertebral segmentation defect with mesomelia [COVEDEM]; see also brachydactyly type B
Robinow syndrome, dominant type	AD	180700				
Mesomelic dysplasia, Korean type	AD		2q24–32			
Mesomelic dysplasia, Kantaputra type	AD	156232	2q24–32			
Mesomelic dysplasia, Nievergelt type	AD	163400				
Mesomelic dysplasia, Kozlowski-Reardon type	AR	249710				
Mesomelic dysplasia with acral synostoses (Verloes–David–Pfeiffer type)	AD	600383	8q13	<i>SULF1 and SLC05A1</i>	Heparan sulfate 6-O- endosulfatase 1 and solute carrier organic anion trans- porter family member 5A1	Microdeletion syndrome involving two adjacent genes

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Mesomelic dysplasia, Savarirayan type (Triangular Tibia—Fibular Aplasia)	SP	605274				Possibly related to Nievergelt dysplasia. One case reported with 2q11.2 microdeletion of unclear significance
18. Bent bones dysplasias						
Campomelic dysplasia (CD)	AD	114290	17q24.3–25.1	SOX9	SRY-box 9	Includes acampomelic campomelic dysplasia (ACD) as well as mild campomelic dysplasia (MIM 602196) Includes formerly neonatal Schwartz–Jampel syndrome or SJS type 2
Strüve–Wiedemann dysplasia	AR	601559	5p13.1	LIFR	Leukemia inhibitory factor receptor	Probably heterogeneous
Kyphomelic dysplasia, several forms <i>Bent bones at birth can be seen in a variety of conditions, including osteogenesis imperfecta, Antley–Bixler syndrome, cartilage-hair hypoplasia, Cummings syndrome, hypophosphatasia, dyssegmental dysplasia, TD, ATD, and others</i>		211350				
19. Slender bone dysplasia group						
3-M syndrome (3M1)	AR	273750	6p21.1	CUL7	Cullin 7	Includes dolichospondylic dysplasia and Yakut short stature syndrome
3-M syndrome (3M2)	AR	612921	2q35	OBSL1	Obscurin-like 1	
Kenny–Caffey dysplasia type 1	AR	244460	1q42–q43	TBCE	Tubulin-specific chaperone E	
Kenny–Caffey dysplasia type 2	AD	127000				
Microcephalic osteodysplastic primordial dwarfism type 1/3 (MOPD1)	AR	210710	2q			Includes Taybi–Linder cephaloskeletal dysplasia
Microcephalic osteodysplastic primordial dwarfism type 2 (MOPD2; Majewski type)	AR	210720	21q	PCNT2	Pericentrin 2	
IMAGE syndrome (intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia, and genital anomalies)	XL/AD	300290				Possibly heterogeneous
Osteocraniostenosis	SP	602361				Occurrence in sibs reported, inheritance unclear
Hallermann–Streiff syndrome	AR	234100				Mutations in GJA1 reported in one case only
<i>See also Cerebro-arthro-digital dysplasia</i>						
20. Dysplasias with multiple joint dislocations						
Desbuquois dysplasia (with accessory ossification center in digit 2)	AR	251450	17q25.3	CANT1		
Desbuquois dysplasia with short metacarpals and elongated phalanges (Kim type)	AR	251450	17q25.3	CANT1		

Desbuquois dysplasia (other variants with or without accessory ossification center)	AR					Probably genetically heterogeneous
Pseudodiastrophic dysplasia	AR	264180				
<i>See also SED with congenital dislocations, CHST3 type (group 4); Ateleosteogenesis type 3 and Larsen syndrome (group 6); SEMDs with joint laxity (group 11)</i>						
21. Chondrodysplasia punctata (CDP) group						
CDP, X-linked dominant,	XLD	302960	Xp11	EBP	Emopamil-binding protein	
Conradi-Hünermann type (CDPX2)						
CDP, X-linked recessive,	XLR	302950	Xp22.3	ARSE	Arylsulfatase E	
brachytelephalangic type (CDPX1)						
Congenital hemidysplasia, ichthyosis, limb defects (CHILD)	XLD	308050	Xp11	NSDHL	NAD(P)H steroid dehydrogenase-like protein	
Congenital hemidysplasia, ichthyosis, limb defects (CHILD)	XLD	308050	Xq28	EBP	Emopamil-binding protein	
Greenberg dysplasia	AR	215140	1q42.1	LBR	Lamin B receptor, 3-beta-hydroxysterol delta [14]-reductase	Includes hydrops-ectopic calcification-moth-eaten appearance dysplasia (HEM) and dappled diaphyseal dysplasia
Rhizomelic CDP type 1	AR	215100	6q22-24	PEX7	Peroxisomal PTS2 receptor	
Rhizomelic CDP type 2	AR	222765	1q42	DHPAT	Dihydroxyacetonephosphate acyltransferase (DHAPAT)	
Rhizomelic CDP type 3	AR	600121	2q31	AGPS	Alkylglycerone-phosphate synthase (AGPS)	
CDP tibial-metacarpal type	AD/AR	118651				Nosologic status uncertain
Astley-Kendall dysplasia	AR?					Relationship to OI and to Greenberg dysplasia unclear
<i>Note that stippling can occur in several syndromes such as Zellweger, Smith-Lemli-Opitz and others. See also desmosterolosis as well as SEMD short limb—abnormal calcification type in group 11</i>						
22. Neonatal osteosclerotic dysplasias						
Blomstrand dysplasia	AR	215045	3p22-21.1	PTHRI	PTH/PTHrP receptor 1	Caused by recessive inactivating mutations; see also Eiken dysplasia and Jansen dysplasia
Desmosterolosis	AR	602398	1p33-31.1	DHCR24	3-beta-hydroxysterol delta-24-reductase	See also other sterol-metabolism related conditions
Caffey disease (including infantile and attenuated forms)	AD	114000	17q21-22	COL1A1	Collagen 1, alpha-1 chain	See also osteogenesis imperfecta related to collagen 1 genes (group 24)
Caffey disease (severe variants with prenatal onset)	AR	114000				
Raine dysplasia (lethal and non-lethal forms)	AR	259775	7p22	FAM20C		Includes lethal and non-lethal cases
<i>See also Astley-Kendall dysplasia and CDPs in group 21</i>						
23. Increased bone density group (without modification of bone shape)						
Osteopetrosis, severe neonatal or infantile forms (OPTB1)	AR	259700	11q13	TCIRG1	Subunit of ATPase proton pump	
Osteopetrosis, severe neonatal or infantile forms (OPTB4)	AR	611490	16p13	CLCN7	Chloride channel 7	

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Osteopetrosis, infantile form, with nervous system involvement (OPTB5)	AR	259720	6q21	<i>OSTM1</i>	Gray lethal/osteopetrosis associated transmembrane protein	
Osteopetrosis, intermediate form, osteoclast-poor (OPTB2)	AR	259710	13q14.11	<i>RANKL</i> [<i>TNFSF11</i>]	Receptor activator of NF-kappa-B ligand (tumor necrosis factor ligand superfamily, member 11)	See also familial expansile osteolysis in Osteolysis group [group 28]
Osteopetrosis, infantile form, osteoclast-poor with immunoglobulin deficiency (OPTB7)	AR	612302	18q21.33	<i>RANK</i> [<i>TNFRSF11A</i>]	Receptor activator of NF-kappa-B	
Osteopetrosis, intermediate form (OPTB6)	AR	611497	17q21.3	<i>PLEKHM1</i>	Pleckstrin homology domain-containing protein, family M, member 1	
Osteopetrosis, intermediate form (OPTA2)	AR	259710	16p13	<i>CLCN7</i>	Chloride channel pump	
Osteopetrosis with renal tubular acidosis (OPTB3)	AR	259730	8q22	<i>CA2</i>	Carbonic anhydrase 2	
Osteopetrosis, late-onset form type 1 (OPTA1)	AD	607634	11q13.4	<i>LRP5</i>	Low density lipoprotein receptor-related protein 5	Includes Worth type osteosclerosis (MIM 144750)
Osteopetrosis, late-onset form type 2 (OPTA2)	AD	166600	16p13	<i>CLCN7</i>	Chloride channel 7	
Osteopetrosis with ectodermal dysplasia and immune defect (OLEDAID)	XL	300301	Xq28	<i>IKBK</i> [<i>NEMO</i>]	Inhibitor of kappa light polypeptide gene enhancer, kinase of	
Osteopetrosis, moderate form with defective leucocyte adhesion (LAD3)	AR	612840	11q12	<i>FERMT3</i> [<i>KIND3</i>]	Fermitin 3 (Kindlin 3)	
Osteopetrosis, moderate form with defective leucocyte adhesion	AR	612840	11q13	<i>RASGRP2</i> [<i>CaIDAG-GEF1</i>]	Ras guanyl nucleotide-releasing protein 2	
Pyknodysostosis	AR	265800	1q21	<i>CTSK</i>	Cathepsin K	
Osteopikilosis	AD	155950	12q14	<i>LEMD3</i>	LEM domain-containing 3	Includes Buschke-Ollendorff syndrome (MIM 166700)
Melorheostosis with osteopikilosis	AD	155950	12q14	<i>LEMD3</i>	LEM domain-containing 3	Includes mixed sclerosing bone dysplasia
Osteopathia striata with cranial sclerosis (OSCS)	XLD	300373	Xq11.1	<i>WTX</i>	FAM123B	
Melorheostosis	SP					No germ line LEMD3 mutations identified so far
Dysosteosclerosis	AR	224300				Possibly related to "osteosclerotic metaphyseal dysplasia"
Osteomesopyknosis	AD	166450				Same as osteopetrosis with nervous system involvement [see above]?
Osteopetrosis with infantile neuroaxonal dysplasia	AR?	600329				

24. Increased bone density group with metaphyseal and/or diaphyseal involvement

Craniometaphyseal dysplasia, autosomal dominant type	AD	123000	5p15.2–14.2	<i>ANKH</i>	Homolog of mouse ANK (ankylosis) gene	Gain of function mutations
Diaphyseal dysplasia	AD	131300	19q13	<i>TGFbeta1</i>	Transforming growth factor beta 1	
Camurati-Engelmann	AR	231095	7q34	<i>TBXAS1</i>	Thromboxane A synthase 1	
Hematodiaphyseal dysplasia Ghosal	AR	259100	4q34–35	<i>HPGD</i>	15-alpha-hydroxyprostaglandin dehydrogenase	Includes cranio-osteoarthropathy and cases of recessive pachydermoperiostosis
Hypertrophic osteoarthropathy	AD	167100				Relationship to recessive form (MIM 259100, HPGD deficiency) unclear
Pachydermoperiostosis (hypertrophic osteoarthropathy, primary, autosomal dominant)	AD	167100				
Oculodentosseous dysplasia (ODOD) mild type	AD	164200	6q22–23	<i>GJA1</i>	Gap junction protein alpha-1	Possibly homozygous form of mild ODOD
Oculodentosseous dysplasia (ODOD) severe type	AR	257850				
Osteoectasia with hyperphosphatasia (juvenile Paget disease)	AR	239000	8q24	<i>OPG</i>	Osteoprotegerin	
Sclerosteosis	AR	269500	17q12–21	<i>SOST</i>	Sclerostin	
Endosteal hyperostosis, van Buchem type	AR	239100	17q12–21	<i>SOST</i>	Sclerostin	Specific 52 kb deletion downstream of <i>SOST</i>
Trichodontoosseous dysplasia	AD	190320	17q21	<i>DLX3</i>	Distal-less homeobox 3	
Craniometaphyseal dysplasia, autosomal recessive type	AR	218400	6q21–22			
Diaphyseal medullary stenosis with bone malignancy	AD	112250	9p21–p22			
Craniodiaphyseal dysplasia	AD	122860				
Craniometadiaphyseal dysplasia, Wormian bone type	AR	—				
Endosteal sclerosis with cerebellar hypoplasia	AR	213002				
Lenz–Majewski hyperostotic dysplasia	SP	151050				
Metaphyseal dysplasia, Braun–Tinschert type	XL	605946				
Pyle disease	AR	265900				

25. Osteogenesis imperfecta and decreased bone density group

For comments the classification of osteogenesis imperfecta, please refer to the text

Osteogenesis imperfecta, non-deforming form (OI type 1)	AD			<i>COL1A1, COL1A2</i>	COL1A1: collagen 1 alpha-1 chain, COL1A2: collagen 1 alpha-2 chain, CRTAP: cartilage-associated protein, LEPRE1: leucine proline-enriched proteoglycan (leprecan) 1, PPIB: peptidylprolyl isomerase B (cyclophilin B), FKBP10: FK506 binding protein 10, SERPINH: serpin peptidase inhibitor clade H 1, SP7: SP7 transcription factor (Osterix)	
Osteogenesis imperfecta, progressively deforming type (OI type 2)	AD, AR			<i>COL1A1, COL1A2, CRTAP, LEPRE1, PPIB, COL1A1, COL1A2, CRTAP, LEPRE1, PPIB, FKBP10, SERPINH1</i>		See also Bruck syndrome type 1 (below)
Osteogenesis imperfecta, moderately deforming type (OI type 3)	AD, AR			<i>COL1A1, COL1A2, CRTAP, FKBP10, SP7</i>		
Osteogenesis imperfecta, moderate form (OI type 4)	AD, AR					

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Osteogenesis imperfecta with calcification of the interosseous membranes and/or hypertrophic callus (OI type 5)	AD	610967				
Osteogenesis imperfecta, other types						
Bruck syndrome type 1 (BS1)	AR	259450	17q21	<i>FKBP10</i>	FK506 binding protein 10	See autosomal recessive OI, above; intrafamilial variability between OI3 and BS1 documented
Bruck syndrome type 2 (BS2)	AR	609220	3q23–24	<i>PLD2</i>	Procollagen lysyl hydroxylase 2	
Osteoporosis-pseudoglioma syndrome	AR	259770	11q12–13	<i>LRP5</i>	LDL-receptor related protein 5	
Calvarial doughnut lesions with bone fragility	AD	126550				
Idiopathic juvenile osteoporosis	SP	259750				Some patients reported with heterozygous mutations in the <i>LRP5</i> gene
Cole-Carpenter dysplasia [bone fragility with craniosynostosis]	SP	112240				See also craniosynostosis syndromes in group 30
Spondylo-ocular dysplasia	AR	605822				Unlinked to collagen 1 and collagen 2 genes or <i>LRP5</i>
Osteopenia with radiolucent lesions of the mandible	AD	166260				
Ehlers–Danlos syndrome, progeroid form	AR	130070	5q35	<i>B4GALT7</i>	Xylosylprotein 4-beta-galactosyltransferase deficiency	
Geroderma osteodysplasticum	AR	231070	1q24.2	<i>GORAB</i>	SCYL1-binding protein 1	
Cutis laxa, autosomal recessive form, type 2B (ARCL2B)	AR	612940	17q25.3	<i>PYCR1</i>	Pyrroline-5-carboxylate reductase 1	Skeletal features overlapping with progeroid EDS and geroderma osteodysplasticum
Cutis laxa, autosomal recessive form, type 2A (ARCL2A) [Wrinkly skin syndrome]	AR	278250, 219200	12q24.3	<i>ATP6V0A2</i>	ATPase, H ⁺ transporting, lysosomal, V0 subunit A2	Skeletal features overlapping with progeroid EDS and geroderma osteodysplasticum
Singleton–Merten dysplasia	AD	182250				Intrafamilial variability
26. Abnormal mineralization group						
Hypophosphatasia, perinatal lethal and infantile forms	AR	241500	1p36.1–p34	<i>ALPL</i>	Alkaline phosphatase, tissue non-specific [TNSALP]	Includes odontohypophosphatasia
Hypophosphatasia, adult form	AD	146300	1p36.1–p34	<i>ALPL</i>	Alkaline phosphatase, tissue non-specific [TNSALP]	

Hypophosphatemic rickets, X-linked dominant	XLD	307800	Xp22	<i>PHEX</i>	X-linked hypophosphatemia membrane protease	Part of Dent's disease complex
Hypophosphatemic rickets, autosomal dominant	AD	193100	12p13.3	<i>FGF23</i>	Fibroblast growth factor 23	
Hypophosphatemic rickets, autosomal recessive, type 1 (ARHR1)	AR	241520	4q21	<i>DMP1</i>	Dentin matrix acidic phosphoprotein 1	
Hypophosphatemic rickets, autosomal recessive, type 2 (ARHR2)	AR	613312	6q23	<i>ENPP1</i>	Ectonucleotide pyrophosphatase/phosphodiesterase 1	
Hypophosphatemic rickets with hypercalciuria, X-linked recessive	XLR	300554	Xp11.22	<i>CICN5</i>	Chloride channel 5	
Hypophosphatemic rickets with hypercalciuria, autosomal recessive (HHRH)	AR	241539	9q34	<i>SLC34A3</i>	Sodium-phosphate cotransporter	
Neonatal hyperparathyroidism, severe form	AR	239200	3q13.3–21	<i>CASR</i>	Calcium-sensing receptor	
Familial hypocalciuric hypercalcemia with transient neonatal hyperparathyroidism	AD	145980	3q13.3–21	<i>CASR</i>	Calcium-sensing receptor	
Calcium pyrophosphate deposition disease (familial chondrocalcinosis) type 2	AD	118600	5p15.2–14.2	<i>ANKH</i>	Homolog of mouse ANK (ankylosis) gene	
See also <i>Jansen dysplasia</i> and <i>Eiken dysplasia</i>						
27. Lysosomal storage diseases with skeletal involvement (dysostosis multiplex group)						
Mucopolysaccharidosis type 1H/1S	AR	607014	4p16.3	<i>IDA</i>	Alpha-1-Iduronidase	Loss of function mutations (see craniometaphyseal dysplasia in group 24)
Mucopolysaccharidosis type 2	XLR	309900	Xq27.3–28	<i>IDS</i>	Iduronate-2-sulfatase	
Mucopolysaccharidosis type 3A	AR	252900	17q25.3	<i>HSS</i>	Heparan sulfate sulfatase	
Mucopolysaccharidosis type 3B	AR	252920	17q21	<i>NAGLU</i>	N-Ac-beta-D-glucosaminidase	
Mucopolysaccharidosis type 3C	AR	252930	8p11–q13	<i>HSGNAT</i>	Ac-CoA: alpha-glucosaminide N-acetyltransferase	
Mucopolysaccharidosis type 3D	AR	252940	12q14	<i>GNS</i>	N-Acetylglucosamine 6-sulfatase	
Mucopolysaccharidosis type 4A	AR	253000	16q24.3	<i>GALNS</i>	Galactosamine-6-sulfate sulfatase	
Mucopolysaccharidosis type 4B	AR	253010	3p21.33	<i>GLBI</i>	beta-Galactosidase	
Mucopolysaccharidosis type 6	AR	253200	5q13.3	<i>ARSB</i>	Arylsulfatase B	
Mucopolysaccharidosis type 7	AR	253220	7q21.11	<i>GUSB</i>	beta-Glucuronidase	
Fucosidosis	AR	230000	1p34	<i>FUCA</i>	alpha-Fucosidase	
alpha-Mannosidosis	AR	248500	19p13.2–12	<i>MANA</i>	alpha-Mannosidase	
beta-Mannosidosis	AR	248510	4q22–25	<i>MANB</i>	beta-Mannosidase	
Aspartylglucosaminuria	AR	208400	4q23–27	<i>AGA</i>	Aspartyl-glucosaminidase	
GMI Gangliosidosis, several forms	AR	230500	3p21–14.2	<i>GLB1</i>	beta-Galactosidase	
Sialidosis, several forms	AR	256550	6p21.3	<i>NEU1</i>	Neuraminidase [sialidase]	
Sialic acid storage disease (SIASD)	AR	269920	6q14–q15	<i>SLC17A5</i>	Sialin (sialic acid transporter)	
Galactosialidosis, several forms	AR	256540	20q13.1	<i>PGCB</i>	beta-Galactosidase protective protein	
Multiple sulfatase deficiency	AR	272200	3p26	<i>SUMF1</i>	Sulfatase-modifying factor-1	
Mucopolipidosis II (I-cell disease), alpha/beta type	AR	252500	4q21–23	<i>GNPTAB</i>	N-Acetylglucosamine 1-phosphotransferase, alpha/beta subunits	

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Mucopolidosis III (Pseudo-Hurler polydystrophy), alpha/beta type	AR	252600	4q21–23	GNPTAB	N-Acetylglucosamine 1-phosphotransferase, alpha/beta subunits	
Mucopolidosis III (Pseudo-Hurler polydystrophy), gamma type	AR	252605	4q21–23	GNPTG	N-Acetylglucosamine 1-phosphotransferase, gamma subunit	
28. Osteolysis group						
Familial expansile osteolysis	AD	174810	18q22.1	RANK (TNFRSF11A)		Includes expansile skeletal hyperphosphatasia (MIM 602080)
Mandibuloacral dysplasia type A	AD	248370	1q21.2	LMNA	Lamin A/C	
Mandibuloacral dysplasia type B	AR	608612	1p34	ZMPSTE24	Zinc metalloproteinase	
Progeria, Hutchinson–Gilford type	AD	176670	1q21.2	LMNA	Lamin A/C	
Torg–Winchester syndrome	AR	259600	16q13	MMP2	Matrix metalloproteinase 2	Includes Nodulosis–Arthropathy–Osteolysis syndrome (MIM 605156)
Hajdu–Cheney syndrome	AD	102500				
Multicentric carpal-tarsal osteolysis with and without nephropathy	AD	166300				
Lipomembraneous osteodystrophy with leukoencephalopathy (presenile dementia with bone cysts; Nasu–Hakola)	AR	221770	6p21.2	TREM2	Triggering receptor expressed on myeloid cells 2	
Lipomembraneous osteodystrophy with leukoencephalopathy (presenile dementia with bone cysts; Nasu–Hakola)	AR	221770	19q13.1	TYROBP	Tyro protein tyrosine kinase-binding protein	
<i>See also Pycnodysostosis, cleidocranial dysplasia, and Singleton–Merten syndrome. Note: several neurologic conditions may cause acroosteolysis</i>						
29. Disorganized development of skeletal components group						
Multiple cartilaginous exostoses 1	AD	133700	8q23–24.1	EXT1	Exostosin-1	
Multiple cartilaginous exostoses 2	AD	133701	11p12–11	EXT2	Exostosin-2	
Multiple cartilaginous exostoses 3	AD	600209	19p			
Cherubism	AD	118400	4p16	SH3BP2	SH3 domain-binding protein 2	
Fibrous dysplasia, polyostotic form	SP	174800	20q13	GNAS1	Guanine nucleotide-binding protein, alpha-stimulating activity subunit 1	Somatic mosaicism and imprinting phenomena; includes McCune–Albright syndrome
Progressive osseous heteroplasia	AD	166350	20q13	GNAS1	Guanine nucleotide-binding protein, alpha-stimulating activity subunit 1	Gene subject to imprinting
Gnathodiaphyseal dysplasia	AD	166260	11p15.1–14.3	TMEM16E	Transmembrane protein 16E	
Metachondromatosis	AD	156250	12q24	PTPN11	Protein-tyrosine phosphatase nonreceptor-type 11	

Osteoglophonic dysplasia	AD	166250	8p11	<i>FGFR1</i>	Fibroblast growth factor receptor 1	See also Craniosynostosis syndromes in group 30
Fibrodysplasia ossificans progressiva (FOP)	AD, SP	135100	2q23–24	<i>ACVR1</i>	Activin A (BMP type 1) receptor	
Neurofibromatosis type 1 (NF1)	AD	162200	17q11.2	<i>NF1</i>	Neurofibromin	
Carpotarsal osteochondromatosis	AD	127820				
Cherubism with gingival fibromatosis	AR	266270				
[Ramon syndrome]						
Dysplasia epiphysealis hemimelica [Trevor]	SP	127800				
Enchondromatosis [Ollier]	SP	166000				<i>PTHR1</i> and <i>PTPN11</i> mutations found in a few cases only, role still unclear <i>PTPN11</i> mutations found in a few cases only, role unclear
Enchondromatosis with hemangiomas [Maffucci]	SP	166000				
See also <i>Proteus syndrome</i> in group 30						
30. Overgrowth syndromes with skeletal involvement						
Weaver syndrome	SP/AD	277590				Some cases reported with <i>NSD1</i> mutations (see Sotos syndrome) Some cases may have <i>NFIX</i> mutations (see Marshall–Smith syndrome)
Sotos syndrome	AD	117550	5q35	<i>NSD1</i>	Nuclear receptor-binding su-var, enhancer of zeste, and trithorax domain protein 1	
Marshall–Smith syndrome	SP	602535	19p13.3	<i>NFIX</i>	Nuclear factor I/X	Some clinical overlap with Sotos syndrome (see above) Some Proteus-like cases have mutations in the <i>PTEN</i> gene
Proteus syndrome	SP	176920				
Marfan syndrome	AD	154700	15q21.1	<i>FBN1</i>	Fibrillin 1	
Congenital contractural arachnodactyly	AD	121050	5q23.3	<i>FBN2</i>	Fibrillin 2	
Loeys–Dietz syndrome types 1A and 2A	AD	609192, 610168, 608967, 610380	9q22	<i>TGFBR1</i>	TGFbeta receptor subunit 1	
Loeys–Dietz syndrome types 1B and 2B	AD		3p22	<i>TGFBR2</i>	TGFbeta receptor subunit 2	
Overgrowth syndrome with 2q37 translocations	SP	—	2q37	<i>NPPC</i>	Natriuretic peptide precursor C	Overgrowth probably caused by overexpression of <i>NPPC</i> Nosologic status unclear but conspicuous skeletal phenotype(s)
Overgrowth syndrome with skeletal dysplasia [Nishimura–Schmidt, endochondral gigantism]	SP?					
See also <i>Shprintzen–Goldberg syndrome</i> in <i>Craniosynostosis group</i>						
31. Genetic inflammatory/rheumatoid-like osteoarthropathies						
Progressive pseudorheumatoid dysplasia (PPRD; SED with progressive arthropathy)	AR	208230	6q22–23	<i>WISP3</i>	WNT1-inducible signaling pathway protein 3	
Chronic infantile neurologic cutaneous articular syndrome [CINCA]/neonatal onset multisystem inflammatory disease (NOMID)	AD	607115	1q44	<i>CIAS1</i>	Cryopyrin	

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Sterile multifocal osteomyelitis, periostitis, and pustulosis (CINCA/NOMID-like)	AR	147679	2q14.2	<i>IL1RN</i>	Interleukin 1 receptor antagonist	
Chronic recurrent multifocal osteomyelitis with congenital dyserythropoietic anemia (CRMO with CDA; Majeeed syndrome)	AR	609628	18p11.3	<i>LPIN2</i>	Lipin 2	
Hyperostosis/hyperphosphatemia syndrome	AR	610233	2q24–q31	<i>GALNT3</i>	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylglucosaminyltransferase 3	
Infantile systemic hyalinosi/Juvenile hyaline fibromatosis (ISH/JHF)	AR	236490	4q21	<i>ANTXR2</i>	Anthrax toxin receptor 2	Includes Juvenile hyaline fibromatosis (JHF, 228600) and Puretic syndrome
32. Cleidocranial dysplasia and isolated cranial ossification defects group						
Cleidocranial dysplasia	AD	119600	6p21	<i>RUNX2</i>	Runt related transcription factor 2	
CDAGS syndrome (craniosynostosis, delayed fontanel closure, parietal foramina, imperforate a.u., genital anomalies, skin eruption)	AR	603116	22q12–q13			
Yunis–Varon dysplasia	AR	216340				
Parietal foramina (isolated)	AD	168500	11q11.2	<i>ALX4</i>	Aristaless-like 4	See also Frontonasal dysplasia type 1 (group 34)
Parietal foramina (isolated)	AD	168500	5q34–35	<i>MSX2</i>	Muscle segment homeobox 2	
<i>See also pycnodysostosis, wrinkly skin syndrome, and several others</i>						
33. Craniosynostosis syndromes						
Pfeiffer syndrome (FGFR1-related)	AD	101600	8p12	<i>FGFR1</i>	Fibroblast growth factor receptor 1	Most have <i>FGFR1</i> P252R mutation (phenotype generally milder than FGFR2-related Pfeiffer)
Pfeiffer syndrome (FGFR2-related)	AD	101600	10q26.12	<i>FGFR2</i>	Fibroblast growth factor receptor 2	Includes Jackson–Weiss syndrome (MIM 123150) and Antley–Bixler variants caused by <i>FGFR2</i> mutations (see below)
Apert syndrome	AD	101200	10q26.12	<i>FGFR2</i>	Fibroblast growth factor receptor 2	
Craniosynostosis with cutis gyrate (Beare–Stevenson)	AD	123790	10q26.12	<i>FGFR2</i>	Fibroblast growth factor receptor 2	
Crouzon syndrome	AD	123500	10q26.12	<i>FGFR2</i>	Fibroblast growth factor receptor 2	

Crouzon-like craniosynostosis with acanthosis nigricans [Crouzonodermoskeletal syndrome]	AD	612247	4p16.3	<i>FGFR3</i>	Fibroblast growth factor receptor 3	Defined by specific <i>FGFR3</i> A391E mutation
Craniosynostosis, Muenke type	AD	602849	4p16.3	<i>FGFR3</i>	Fibroblast growth factor receptor 3	Defined by specific <i>FGFR3</i> P250R mutation
Antley-Bixler syndrome	AR	201750	7q11.23	<i>POR</i>	Cytochrome P450 oxidoreductase	Similar cases with <i>FGFR2</i> mutations classified as Pfeiffer syndrome (MIM 207410)
Craniosynostosis Boston type	AD	604757	5q35.2	<i>MSX2</i>	MSX2	Heterozygous P148H mutation in a single family
Saethre-Chotzen syndrome	AD	101400	7p21.1	<i>TWIST1</i>	TWIST	Some cases reported with <i>FBN1</i> mutations
Shprintzen-Goldberg syndrome	AD	182212				<i>RECQL4</i> might not account for all cases of Baller-Gerold
Baller-Gerold syndrome	AR	218600	8q24.3	<i>RECQL4</i>	RECQ protein-like 4	
Carpenter syndrome	AR	201000		<i>RAB23</i>		
<i>See also Cole-Carpenter syndrome in group 24, CDAGS syndrome in group 29, and Craniofrontonasal syndrome in group 34</i>						
34. Dysostoses with predominant craniofacial involvement						
Mandibulo-facial dysostosis [Treacher Collins, Franceschetti-Klein]	AD	154500	5q32	<i>TCOF1</i>	Treacher Collins-Franceschetti syndrome 1	
Mandibulo-facial dysostosis [Treacher-Collins, Franceschetti-Klein]	AD	154500	13q12.2	<i>POLR1D</i>	Polymerase (RNA) I polypeptide D	
Mandibulo-facial dysostosis [Treacher-Collins, Franceschetti-Klein]	AR	154500	6p21.1	<i>POLR1C</i>	Polymerase (RNA) I polypeptide C	
Oral-facial-digital syndrome type I [OFD1]	XLR	311200	Xp22.3	<i>CXORF5</i>	chr. X open reading frame 5	
Weyer acrofacial [acrodontal] dysostosis	AD	193530	4p16	<i>EVC1</i>	Ellis-van Creveld 1 protein	
Endocrine-cerebro-osteodysplasia [ECO]	AR	612651	6p12.3	<i>ICK</i>	Intestinal cell kinase	
Craniofrontonasal syndrome	XLD	304110	Xq13.1	<i>EFNB1</i>	Ephrin B1	
Frontonasal dysplasia, type 1	AR	136760	1p13.3	<i>ALX3</i>	Aristaless-like-3	
Frontonasal dysplasia, type 2	AR	613451	11p11.2	<i>ALX4</i>	Aristaless-like-4	
Frontonasal dysplasia, type 3	AR	613456	12q21.3	<i>ALX1</i>	Aristaless-like 1	
Hemifacial microsomia	SP/AD	164210				Includes Goldenhar syndrome and Oculo-Auriculo-Vertebral spectrum; probably genetically heterogeneous
Miller syndrome (postaxial acrofacial dysostosis)	AR	263750	16q22	<i>DHODH</i>	Dihydroorotate dehydrogenase	
Acrofacial dysostosis, Nager type	AD/AR	154400				
Acrofacial dysostosis, Rodriguez type	AR	201170				
<i>See also Oral-facial-digital syndrome type IV in the Short Rib Dysplasias group</i>						
35. Dysostoses with predominant vertebral with and without costal involvement						
Curarino triad	AD	176450	7q36	<i>HLXB9</i>	Homeobox gene HB9	
Spondylocostal dysostosis type 1 [SCD1]	AR	277300	19q13	<i>DLL3</i>	Delta-like 3	

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Spondylocostal dysostosis type 2 [SCD2]	AR	608681	15q26	MESP2	Mesoderm posterior (expressed in) 2	
Spondylocostal dysostosis type 3 [SCD3]	AR?	609813	7p22	LFNG	Lunatic fringe	
Spondylocostal dysostosis type 4 [SCD4]	AR		17p13.1	HES7	Hairy-and-enhancer-of-split-7	
Spondylothoracic dysostosis	AR		15q26	MESP2	Mesoderm posterior (expressed in) 2	
Klippel-Feil anomaly with laryngeal malformation	AD	148900	8q22.1	GDF6	Growth and differentiation factor 6	Role of <i>GDF6</i> mutations in dominant spondylothoracic dysostosis unclear See also <i>GDF6</i> , above
Spondylocostal/thoracic dysostosis, other forms	AD/AR					
Cerebro-costo-mandibular syndrome [rib gap syndrome]	AD/AR	117650				
Cerebro-costo-mandibular-like syndrome with vertebral defects	AR	611209	17q25	COG1	Component of oligomeric Golgi complex 1	Also classified as CDG type IIg
Diaphanospondylydysostosis	AR	608022	7p14	BMPER	Bone morphogenetic protein-binding endothelial cell precursor-derived regulator	Possibly overlaps with ischiopsinal dysostosis
See also <i>Spondylocarpotarsal dysplasia</i> in group 7 and <i>spondylo-metaphyseal-megaeipiphyseal dysplasia</i> in group 13						
36. Patellar dysostoses						
Ischiopatellar dysplasia [small patella syndrome]	AD	147891	17q21-q22	TBX4	T-box gene 4	
Small patella—like syndrome with clubfoot	AD		5q31	PITX1	Paired-like homeodomain transcription factor 1 (pituitary homeobox 1)	Includes isolated dominant familial clubfoot
Nail-patella syndrome	AD	161200	9q34.1	LMX1B	LIM homeobox transcription factor 1	
Genitopatellar syndrome	AR?	606170				
Ear-patella-short stature syndrome [Meier-Gorlin]	AR	224690				
See also <i>MED</i> group for conditions with patellar changes as well as <i>ischio-pubic-patellar dysplasia</i> as mild expression of <i>campomelic dysplasia</i>						
37. Brachydactylies [with or without extraskeletal manifestations]						
Brachydactyly type A1	AD	112500	2q35-36	IHH	Indian Hedgehog	
Brachydactyly type A1	AD		5p31			
Brachydactyly type A2	AD	112600	4q23	BMPR1B	Bone morphogenetic protein receptor, 1B	
Brachydactyly type A2	AD	112600		BMP2	Bone morphogenetic protein type 2	
Brachydactyly type A2	AD	112600	20q11.2	GDF5	Growth and differentiation factor 5	
Brachydactyly type A3	AD	112700				

Brachydactyly type B	AD	113000	9q22	<i>ROR2</i>	Receptor tyrosine kinase-like orphan receptor 2	See also Robinow syndrome/COVESEDEM
Brachydactyly type B2	AD	611377	17q	<i>NOG</i>	Noggin	
Brachydactyly type C	AD, AR	113100	20q11.2	<i>GDF5</i>	Growth and differentiation factor 5	See also ASPED (group 14) and other <i>GDF5</i> disorders
Brachydactyly type D	AD	113200	2q31	<i>HOXD13</i>	Homeobox D13	
Brachydactyly type E	AD	113300	12p11.22	<i>PTH1L</i>	Parathyroid hormone-like hormone (parathyroid hormone related peptide, PTHRP)	
Brachydactyly type E	AD	113300	2q31	<i>HOXD13</i>	Homeobox D13	Some patients have microdeletions involving contiguous genes (chr. 2q37 deletion syndrome)
Brachydactyly—mental retardation syndrome	AD	600430	2q37.3	<i>HDAC4</i>	Histone deacetylase 4	
Hyperphosphatasia with mental retardation, brachytelephalangy, and distinct face	AR		1p36.11	<i>PIGV</i>	Phosphatidylinositol-glycan biosynthesis class V protein (GPI mannosyltransferase 2)	Possibly <i>PTH1L</i>
Brachydactyly-hypertension syndrome (Bilginturian)	AD	112410	12p12.2–11.2			Regulatory mutations
Brachydactyly with anonychia (Cooks syndrome)	AD	106995	17q24.3	<i>SOX9</i>		
Microcephaly-oculo-digito-esophageal-duodenal syndrome (Feingold syndrome)	AD	164280	2p24.1	<i>MYCN</i>	nMYC oncogene	
Hand-foot-genital syndrome	AD	140000	7p14.2	<i>HOXA13</i>	Homeobox A13	
Brachydactyly with elbow dysplasia (Liebenberg syndrome)	AD	186550				
Keutel syndrome	AR	245150	12p13.1–12.3	<i>MGP</i>	Matrix Gla protein	See also polyostotic fibrous dysplasia and progressive osseous heteroplasia, group 28
Albright hereditary osteodystrophy (AHO)	AD	103580	20q13	<i>GNAS1</i>	Guanine nucleotide binding protein of adenylate cyclase—subunit	
Rubinstein-Taybi syndrome	AD	180849	16p13.3	<i>CREBBP</i>	CREB-binding protein	
Rubinstein-Taybi syndrome	AD	180849	22q13	<i>EP300</i>	E1A-binding protein, 300-kDa	
Catell-Manzke syndrome	XLR?	302380				
Brachydactyly, Temtamy type	AR	605282				
Christian type brachydactyly	AD	112450				
Coffin-Siris syndrome	AR	135900				
Mononen type brachydactyly	XLD?	301940				
Poland anomaly	SP	173800				
See also group 20 for other conditions with brachydactyly as well as brachytelephalangic CDP						
38. Limb hypoplasia—reduction defects group						
Ulnar-mammary syndrome	AD	181450		<i>TBX3</i>	T-box gene 3	
de Lange syndrome	AD	122470	5p13.1	<i>NIPBL</i>	Nipped-B-like	
Fanconi anemia (see note below)	AR	227650	Several	Several		Several complementation groups and genes

(Continued)

TABLE 1(Continued)

Group/name of disorder	Inheritance	MIM No.	Locus	Gene	Protein	Notes
Thrombocytopenia-absent radius (TAR)	AR?/AD?	274000	1q21.1	Several		Microdeletion on 1q21.1
Thrombocythemia with distal limb defects	AD		3q27	THPO	Thrombopoietin	Distal limb defects postulated as consequence of vascular occlusions
Holt–Oram syndrome	AD	142900	12q24.1	TBX5	T-box gene 5	
Okimoto syndrome (Duane—radial ray anomaly)	AD	607323	20q13	SALL4	SAL-like 4	
Cousin syndrome	AR	260660	1p13	TBX15	T-box gene 15	
Roberts syndrome	AR	268300	8p21.1	ESCO2	Homolog of establishment of cohesion—2	
Split-hand-foot malformation with long bone deficiency (SHFLD1)	AD	119100	1q42.2–q43			
Split-hand-foot malformation with long bone deficiency (SHFLD2)	AD	610685	6q14.1			
Split-hand-foot malformation with long bone deficiency (SHFLD3)	AD	612576	17p13.1			
Tibial hemimelia	AR	275220				
Tibial hemimelia-polysyndactyly-triphalangeal thumb	AD	188770				
Acheiropodia	AR	200500	7q36	LMBR1	Putative receptor protein	Partial LMBR1 deletion affecting expression of Sonic Hedgehog (SHH) gene
Tetra-amelia	XL	301090				
Tetra-amelia	AR	273395	17q21	WNT3	Wingless-type MMTV integration site family, member 3	
Ankyloblepharon-ectodermal dysplasia-cleft lip/palate (AEC)	AD	106260	3q27	P63 (TP63)	Tumor protein p63	
Ectrodactyly-ectodermal dysplasia cleft-palate syndrome Type 3 (EEC3)	AD	604292	3q27	P63 (TP63)	Tumor protein p63	
Ectrodactyly-ectodermal dysplasia cleft-palate syndrome type 1 (EEC1)	AD	129900	7q11.2–12.3			
Ectrodactyly-ectodermal dysplasia-macular dystrophy syndrome (EEM)	AR	225280	16q22	CDH3	Cadherin 3	
Limb-mammary syndrome (including ADULT syndrome)	AD	603273	3q27	P63 (TP63)	Tumor protein p63	
Split hand-foot malformation, isolated form, type 4 (SHFM4)	AD	605289	3q27	P63 (TP63)	Tumor protein p63	
Split hand-foot malformation, isolated form, type 1 (SHFM1)	AD	183600	7q21.3–22.1			
Split hand-foot Malformation, isolated form, type 2 (SHFM2)	XL	313350	Xq26			
Split hand-foot malformation, isolated form, type 3 (SHFM3)	AD	600095	10q24	FBXW4	Dactylin	
Split hand-foot malformation, isolated form, type 5 (SHFM5)	AD	606708	2q31			

Al-Awadi Raas—Rothschild limb-pelvis hypoplasia—aplasia Fuhrmann syndrome	AR	276820	3p25	WNT7A	Wingless-type MMTV integration site family, member 7A	Some phenotypic overlap with FFU syndrome [below]
RAPADILINO syndrome	AR	266280	8q24.3	RECQL4	Wingless-type MMTV integration site family, member 7A RECQ protein-like 4	
Adams—Oliver syndrome	AD/AR	100300				
Femoral hypoplasia-unusual face syndrome [FHUFS]	SP/AD?	134780				
Femur-fibula-ulna syndrome (FFU)	SP?	228200				Some phenotypic overlap with FFU syndrome [below]
Hanhart syndrome	AD	103300				
(hypoglossia—hypodactylia)						
Scapulo-iliac dysplasia (Kosenow)	AD	169550				
Note: the particularly complex genetic basis of Fanconi anemia and its complementation groups are acknowledged but not further listed in this Nosology. The Reader is referred to MIM or to specialized reviews. See also CHILD in group 20 and the mesomelic and acromesomelic dysplasias						
39. Polydactyly—Syndactyly—Triphalangism group						
Preaxial polydactyly type 1 (PPD1)	AD	174400	7q36	SHH	Sonic Hedgehog	Regulatory mutation
Preaxial polydactyly type 1 (PPD1)	AD	174400				Some instances not linked to SHH
Preaxial polydactyly type 2 (PPD2)/ triphalangeal thumb [TPT]	AD	174500	7q36	SHH	Sonic Hedgehog	Regulatory mutation
Preaxial polydactyly type 3 (PPD3)	AD	174600				
Preaxial polydactyly type 4 (PPD4)	AD	174700	7p13	GLI3	Gli-Kruppel family member 3	
Greig cephalopolysyndactyly syndrome	AD	175700	7p13	GLI3	Gli-Kruppel family member 3	
Pallister—Hall syndrome	AD	146510	7p13	GLI3	Gli-Kruppel family member 3	
Synpolydactyly [complex, fibulin1—associated]	AD	608180	22q13.3	FBLN1	Fibulin 1	
Synpolydactyly	AD	186000	2q31	HOXD13	Homeobox D13	
Townes—Brocks syndrome [Renal-Ear-Anal-Radial syndrome]	AD	107480	16q12.1	SALL1	SAL-like 1	
Lacrimo-auriculo-dento-digital syndrome	AD	149730	10q26.12	FGFR2	Fibroblast growth factor receptor 2	
[LADD]						
Lacrimo-auriculo-dento-digital syndrome	AD	149730	4p16.3	FGFR3	Fibroblast growth factor receptor 3	
[LADD]						
Lacrimo-auriculo-dento-digital syndrome	AD	149730	5p13–p12	FGF10	Fibroblast growth factor 10	
[LADD]						
Acrocallosal syndrome	AR	200990	7p13			
Acro-pectoral syndrome	AD	605967	7q36			
Acro-pectoro-vertebral dysplasia [F-syndrome]	AD	102510	2q36			
Mirror-image polydactyly of hands and feet [Laurin—Sandrow syndrome]	AD	135750	7q36	SHH	Sonic Hedgehog	Unlinked to SHH
Mirror-image polydactyly of hands and feet [Laurin—Sandrow syndrome]						
Cenani—Lenz syndactyly	AR	212780	11p11.2	LRP4	Low density lipoprotein receptor-related protein 4	

(Continued)

each gene separately, advocated by some scholars, is more confusing than helpful in clinical practice.

Group 26 has seen the identification of several novel molecular mechanisms leading to hypophosphatemic rickets.

In Group 29 (Disorganized Development of Skeletal Components), neurofibromatosis type 1 has been included following the points made by Stevenson and others that although the main clinical features of NF1 are neurologic and cutaneous, the skeletal features are frequent, diagnostically helpful and clinically relevant [Stevenson et al., 2007].

Groups 30 (Overgrowth syndromes with significant skeletal involvement) and Group 31 (Genetic inflammatory/rheumatoid-like osteoarthropathies) have been newly added. Group 30 comprises disorders that present as overgrowth syndromes and have a significant skeletal component that is part of the diagnostic criteria for a specific condition. One condition has been tentatively included because of its conspicuous skeletal features [Nishimura et al., 2004; Schmidt et al., 2007]; however this condition remains incompletely delineated. Group 31 includes disorders with features of inflammation and skeletal involvement. The creation of these two groups has been suggested by the frequent diagnostic overlap between these disorders and primary skeletal disorders as well as by the identification of the genetic basis of such disorders in recent years, allowing for a more precise delineation of the phenotypes.

Finally, groups 32–40 are dedicated to the dysostoses and follow again anatomical criteria (cranium, face, axial skeleton, extremities) with additional criteria reflecting principles of embryonic development such as limb reduction or hypoplasia (proximal-distal growth) versus terminal differentiation and patterning of the digits or joint formation. These groups have seen a marked increase in conditions with identified molecular bases and there are indications of a much larger heterogeneity yet.

A single group, the Brachyolmias (formerly group 13), has been deleted. Following the inclusion of dominant brachyolmia in the TRPV4 group, the few remaining short-trunk disorders have been incorporated in the SED group.

DISCUSSION

Why “Groups”?

The assignment of individual disorders into groups has been practiced since the first versions of the “Nomenclature.” At that time, with little biochemical or molecular information available, the grouping of disorders reflected the belief that disorders with similar phenotypic features (e.g., *dysostosis multiplex*) might be caused by disturbances in related metabolic pathways or gene networks (in the case of dysostosis multiplex, lysosomal degradation). This notion has been confirmed by the identification of biochemically related groups, such as those of mineralization disorders or lysosomal disorders, and of genetic families such as the collagen 2 family, the FGFR3 family, and the DTDST family. The grouping of disorders is necessary because of the sheer number of conditions included, and can be helpful in making a differential diagnosis based on the main phenotypic findings, for example, in the mesomelic dysplasias or in chondrodysplasia punctata. Some groups are still defined by common radiographic features or by anatomical site involved. More-

over, the nosology committee recognizes that some readers may disagree with our placement of a clinical entity into one group, when it may fit equally well in another group.

Which Classification Criteria to Use?

Criticism to the previous versions of the Nosology has focused on its “hybrid” nature, in the sense that it does not stick to a single systematic approach, be it clinical or molecular. This hybrid nature is intrinsic to the process of unraveling the underlying bases of skeletal diseases; disorders are classified on phenotypic similarities first, and as their molecular bases become understood they may be reclassified based on the gene or pathway that is abnormal. The first aim of the Nosology is to provide a reference list, and only secondarily to help in the diagnostic process. It must therefore coexist with other classifications that are based either on the clinical and radiographic approach to diagnosis, or the affected molecular systems and pathways. As more and more resources are published on the World Wide Web, crosslinking between classifications and databases may facilitate their simultaneous use.

Although care has been given to apply the inclusion criteria uniformly, there are disorders without proven molecular or biochemical defect for which inclusion in the Nosology as distinct entities seem somewhat arbitrary. For these disorders, discussion within the Nosology group, where individual opinions can be harmonized and, if needed, corrected by the collective expertise, is of great importance. Moreover, there are disorders listed in MIM that have not met our inclusion criteria, in most instances because of too few observations or because of the lack of features allowing clear diagnostic distinction from other disorders. It is likely that additional observations or the demonstration of a distinct molecular basis will allow for the inclusion of many of these disorders in the future, either as separate entities or as “variants” of already existing ones.

Dysplasias Versus Dysostoses

Dysostoses are disorders affecting individual bones or group of bones. In contrast to the “dysplasias,” that arise frequently from defects in structural proteins, metabolic processes or in growth plate regulation, the dysostoses often arise from embryonic morphogenic defects and are thus more closely related to multiple malformation syndromes. Since the first inclusion of dysostoses in the 2001 revision, the number of “dysostoses” included in the Nosology has grown significantly. The present revision includes an even larger number of dysostoses reflecting the advances made in identifying their molecular basis. The boundaries between skeletal dysplasias and dysostoses, metabolic and molecular disorders, and multiple congenital anomalies syndromes is becoming progressively less sharp, and the diagnostic process requires knowledge that crosses between these subspecialty areas; the group of (cranio-)frontonasal disorders and the Franck–ter Haar syndrome can be cited as examples. The MIM catalogue contains many more entries, such as multiple malformation syndromes, that have some degree of skeletal involvement. Emphasis has been given to syndromes in which the skeletal component is prominent and/or essential to the diagnosis.

OMIM and the Nosology

Because of the importance of consistency between parallel databases, the relationship between the Nosology and the OMIM database has been reviewed. The more comprehensive nature of the data collection and filing in MIM and the different nature of its revision process can lead to a divergence between the inclusion of nosologic entities and their denomination. Thus, MIM is in general more appositional, while the Nosology tries to do some “housekeeping” of entities by regrouping them and by eliminating those that have been incorporated into others. Efforts to made to harmonize the MIM and the Nosology are underway.

Outlook

The increasing availability of massive parallel sequencing and other new sequencing technologies will likely result in a rapid identification of novel disease-causing genes, but also in novel phenotypes associated with mutations in genes already linked to other phenotypes. In the near future, the catalog of skeletal phenotypes with a genetic basis may become so large as to surpass the scope of a “Nosology” as we understand it presently, and the Nosology will transform into an annotated database.

Even in that case, the many revisions of the Nosology will hopefully have paved the way by setting standards for the recognition and definition of skeletal phenotypes. Past versions of the Nosology have been translated in different languages and have found their way into textbooks of pediatrics and genetics. At present, the Nosology may help the clinician who is struggling for a diagnosis, by providing a simple listing of disorders grouped by cardinal features. The Nosology offers a quick reminder of the many differential diagnoses for one given disorder. As an expert-reviewed list of currently recognized disorders, the Nosology also constitutes a standard against which a possible “new” disorder should be compared. Finally, the Nosology offers a catalogue of genes involved in skeletal development and homeostasis that will be of interest and of inspiration to all those who are working in skeletal biology and medicine.

ACKNOWLEDGMENTS

M.L.W. is an Investigator with the Howard Hughes Medical Institute, and A.S.F. is supported by the Leenaards Foundation (Lausanne, Switzerland) and by the Faculté de Biologie et Médecine of the Lausanne University.

REFERENCES

1970. International nomenclature of constitutional diseases of bones. *Ann Radiol (Paris)* 13:455–464.
- 1971a. A nomenclature for constitutional (intrinsic) diseases of bones. *J Pediatr* 78:177–179.
- 1971b. International nomenclature of constitutional bone diseases. Constitutional bone diseases without known pathogenesis. *Arch Fr Pediatr* 28:553–557.
- 1971c. Nomenclature for constitutional (intrinsic) diseases of bones. *Pediatrics* 47:431–434.
- 1971d. Nomenclature for the constitutional (intrinsic) diseases of bone. *Radiology* 99:699–702.
1978. International nomenclature of constitutional diseases of bone. Revision—May, 1977. *J Pediatr* 93:614–616.
1979. International nomenclature of constitutional diseases of bone: Revision—May 1977. *Am J Med Genet* 3:21–26.
1983. International nomenclature of constitutional diseases of bone. Revision, May, 1983. *Ann Radiol (Paris)* 26:457–462.
1998. International nomenclature and classification of the osteochondrodysplasias (1997). International working group on constitutional diseases of bone. *Am J Med Genet* 79:376–382.
- Hall CM. 2002. International nosology and classification of constitutional disorders of bone (2001). *Am J Med Genet* 113:65–77.
- Lachman RS. 1998. International nomenclature and classification of the osteochondrodysplasias (1997). *Pediatr Radiol* 28:737–744.
- McKusick VA, Scott CI. 1971. A nomenclature for constitutional disorders of bone. *J Bone Joint Surg Am* 53:978–986.
- Nishimura G, Hasegawa T, Kinoshita E, Tanaka Y, Kurosawa K, Yoshimoto M. 2004. Newly recognized syndrome of metaphyseal undermodeling, spondylar dysplasia, and overgrowth: Report of two adolescents and a child. *Am J Med Genet Part A* 128A:204–208.
- Rimoin DL. 1979. International nomenclature of constitutional diseases of bone with bibliography. *Birth Defects Orig Artic Ser* 15:30.
- Schmidt H, Kammer B, Grasser M, Enders A, Rost I, Kiess W. 2007. Endochondral gigantism: A newly recognized skeletal dysplasia with pre- and postnatal overgrowth and endocrine abnormalities. *Am J Med Genet Part A* 143A:1868–1875.
- Sillence DO, Rimoin DL. 1978. Classification of osteogenesis imperfecta. *Lancet* 1:1041–1042.
- Sillence DO, Rimoin DL, Danks DM. 1979a. Clinical variability in osteogenesis imperfecta—variable expressivity or genetic heterogeneity. *Birth Defects Orig Artic Ser* 15:113–129.
- Sillence DO, Senn A, Danks DM. 1979b. Genetic heterogeneity in osteogenesis imperfecta. *J Med Genet* 16:101–116.
- Spranger J. 1992. International classification of osteochondrodysplasias. The international working group on constitutional diseases of bone. *Eur J Pediatr* 151:407–415.
- Stevenson DA, Viskochil DH, Carey JC. 2007. Neurofibromatosis type 1 is a genetic skeletal disorder. *Am J Med Genet Part A* 143A:2082–2083;author reply 2084.
- Superti-Furga A, Unger S. 2007. Nosology and classification of genetic skeletal disorders: 2006 revision. *Am J Med Genet Part A* 143A:1–18.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Warman, ML;Cormier-Daire, V;Hall, C;Krakow, D;Lachman, R;LeMerrer, M;Mortier, G;Mundlos, S;Nishimura, G;Rimoin, DL;Robertson, S;Savarirayan, R;Sillence, D;Spranger, J;Unger, S;Zabel, B;Superti-Furga, A

Title:

Nosology and Classification of Genetic Skeletal Disorders: 2010 Revision

Date:

2011-05-01

Citation:

Warman, M. L., Cormier-Daire, V., Hall, C., Krakow, D., Lachman, R., LeMerrer, M., Mortier, G., Mundlos, S., Nishimura, G., Rimoin, D. L., Robertson, S., Savarirayan, R., Sillence, D., Spranger, J., Unger, S., Zabel, B. & Superti-Furga, A. (2011). Nosology and Classification of Genetic Skeletal Disorders: 2010 Revision. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 155A (5), pp.943-968. <https://doi.org/10.1002/ajmg.a.33909>.

Persistent Link:

<http://hdl.handle.net/11343/264780>

License:

[CC BY](#)